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Background: A new dietary supplement, Fatigue Reviva™, has been recently developed to address issues related to
amino acid depletion following illness or in conditions of sub-health where altered amino acid homeostasis has
been associated with fatigue. Complex formulations of amino acids present significant challenges due to solubility
and taste constraints. This initial study sets out to provide an initial appraisal of product palatability and to gather
pilot evidence for efficacy.
Methods: Males reporting symptoms of sub-health were recruited on the basis of being free from any significant
medical or psychological condition. Each participant took an amino acid based dietary supplement (Fatigue
Reviva™) daily for 30 days. Comparisons were then made between pre- and post-supplement general health
symptoms and urinary amino acid profiles.
Results: Seventeen men took part in the study. Following amino acid supplementation the total Chalder fatigue
score improved significantly (mean ± SEM, 12.5 ± 0.9 versus 10.0 ± 1.0, P<0.03). When asked whether they thought
that the supplement had improved their health, 65% of participants responded positively. A subgroup of
participants reported gastrointestinal symptoms which were attributed to the supplement and which were believed
to result from the component fructooligosaccharide. Analysis of urinary amino acids revealed significant alterations
in the relative abundances of a number of amino acids after supplementation including an increase in valine,
isoleucine and glutamic acid and reduced levels of glutamine and ornithine. Discriminant function analysis of the
urinary amino acid data revealed significant differences between the pre- and post-supplement urine excretion
profiles.
Conclusions: The results indicated that Fatigue Reviva™ was palatable and that 65% of the study group reported
that they felt the product had improved their health. The product could provide an effective tool for the
management of unexplained fatigue and symptoms of sub-health. Further product development may yield
additional options for those patients susceptible to fructooligosaccharide.
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The World Health Organisation defines health as “a
state of complete physical, mental and social well-being
and not merely the absence of disease or infirmity” [1].
In contrast, sub-health has been described as a chronic
condition of unexplained deteriorated physiological
function which falls between health and illness [2]. Sub-
health is usually indicated by the presence of lowered
energy levels, loss of vitality, altered sleeping patterns
and an increased incidence of viral infections all occur-
ring in the absence of a defined disease diagnosis [2].
The more severe cases of sub-health may present as
conditions such as chronic fatigue syndrome (CFS) and
fibromyalgia. In the past, interest in the treatment of
fatigue has focussed on the more severe fatigue states of
cancer-related fatigue (CRF) and CFS. The aetiology of
both CFS and CRF remain largely unknown and no ef-
fective treatment strategies have yet been agreed upon.
There is an increasing need for scientifically validated
therapies which can effectively and simply treat the
symptoms of sub-heath including fatigue.
Research into the underlying causes of CFS and CRF
has revealed the presence of altered amino acid homeosta-
sis in these conditions [3-6]. Altered amino acid levels
have been demonstrated by the current research team in
association with sub-health conditions including chronic
fatigue [3] and fatigue in radiotherapy breast cancer pa-
tients [6]. In a relatively large study, depletion of excreted
amino acids in CFS was demonstrated in comparison to
non-fatigued controls [7]. Results of metabolic profiling
have pointed to the presence of a chronic catabolic state
associated with sub-health. A catabolic state is usually
acute and transient and may occur in response to trauma,
physical exertion or infection. It has been proposed that in
sub-health, a long-term catabolic state exists resulting in
cellular malnutrition as evidenced by particular deficits in
amino acids [2]. Dunstan [8] demonstrated that a range of
different states of phenotypic amino acid homeostasis
exist, where some may require higher dietary levels of par-
ticular amino acids. An increased requirement for amino
acids may not be limited to the essential amino acids.
Although essential amino acids must be derived from the
diet as they cannot be synthesised by humans, some non-
essential amino acids may also become “conditionally es-
sential” as the body’s rate of synthesis may not meet the
required demand. If these nutritional demands are not
met, increased susceptibility to environmental challenges
may occur and a state of sub-health may result [8].
Amino acid supplementation has been shown to
stimulate the immune system [9,10], enhance recovery
of the critically ill [11] and maintain gut function [12] as
well as alleviate symptoms of CFS [5] and CRF [13].
During exercise, supplementation with branched chain
amino acids (BCAAs) has been shown to improveperformance, possibly through a reduction in fatigue
[14]. It has been proposed that as a result of supplemen-
tation, changes in the plasma tryptophan to BCAA ratio
could affect CNS uptake of tryptophan and resultant 5-
hydroxytryptamine synthesis which is believed to be
involved in fatigue during prolonged exercise [14]. Sup-
plementation of mice with BCAAs has also been shown
to improve physical endurance and motor coordination
and increased life span with an associated increase in
cardiac and skeletal muscle mitochondrial biogenesis
and function [15]. Branched chain amino acid levels
have been shown to be reduced in CFS with deficits in
BCAA availability having the capacity to impact upon
brain function via CNS glutamate and glutamine homeo-
stasis [7].
A dietary supplement, Fatigue Reviva™, has recently
been developed by TOP Nutrition Pty Ltd to address
issues related to amino acid depletion in conditions of
sub-health. Development of a product endeavouring to
provide broad-spectrum amino acid supplementation
with the associated vitamins and cofactors required for
effective utilisation, presents significant challenges. The
supplement mixture needs to be formulated to comply
with food industry standards, accommodate solubility
and palatability issues, and have minimal adverse im-
pacts. This initial study represents a preliminary phase
of testing of Fatigue Reviva™ to appraise palatability and
feedback on the use of the product whilst gathering
pilot evidence on the potential to reduce symptoms of
fatigue. If further product development was required as
a result, this should be completed before a larger scale
double-blinded and placebo-controlled trial would be
implemented. This first stage of product development
investigated the use of Fatigue Reviva™ over a thirty-day
period in a group of healthy men experiencing some
symptoms of sub-health. Symptoms were appraised and
urine samples were analysed for amino acid com-
position before and after the supplementation period.
Feedback on palatability and usage were recorded and
collated at the end of the supplementation period for
each participant.
Since the product under development was not a drug,
this investigation did not fall under the phase 1 or phase 2
definitions of a drug trial. Safe daily doses of each of the
amino acids have already been determined and dosage
limits are governed by the NSW Food Authority restric-
tions. The product under testing was a food category
product. All ingredients used in this product conform to
the regulations set out in the Foods Standards Code
(FSANZ) [16], the NSW Food Act 2003 [17] and the
NSW Food Registration 2010 [18]. To reduce heterogen-
eity within this initial group, only male participants were
included. The study will be further extended in the future
to include females.
Table 1 Chalder fatigue scale scores (mean ± SEM) for a









Mean (SEM) Mean (SEM)
Total fatigue 12.5 (0.9) 10.0 (1.0) P < 0.03
Physical fatigue 7.6 (0.5) 6.1 (0.7) P < 0.03
Mental fatigue 4.8 (0.5) 3.9 (0.3) ns
Statistical test: Mann–Whitney U test, P < 0.05.
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Sub-health was defined as subjects experiencing reduced
energy levels, change in sleeping patterns, increased inci-
dence of infections and loss of vitality. Subjects who
reported experiencing symptoms of sub-health but were
otherwise healthy were recruited from patients of health
practitioners and from the general public. The majority of
participants (n=15) were recruited from the general public.
Potential participants were excluded from the study if they
reported a previous or current diagnosis of a significant
medical (e.g. heart disease) or psychiatric (e.g. depression)
condition. Two participants were excluded on the basis of
mental illness. Participants were required to take 20g of
the amino acid based dietary supplement (Fatigue Reviva™)
blended in 100 ml of water each day for 30 days. The nu-
tritional supplement comprised an amino acid complex,
containing both essential and non-essential amino acids at
doses compliant with the Australian Food Standards Code,
the NSW Food Act 2003 and the NSW Food Registration
2010, carbohydrates including fructooligosaccharide (FOS)
and vitamins and minerals. Prior to supplementation and
the day following the completion of supplementation, sub-
jects were required to provide a fasted first-morning urine
sample collected in a Urine-Monovette® 10 ml boric acid
tube (Sarstedt, Germany) and to complete two question-
naires. Participants were assessed for fatigue using the
Chalder fatigue scale [19] (11-items, Likert scored). Partic-
ipants were also assessed for current general health and
well-being using an 86 item questionnaire developed and
extensively used by the current research team [20-22].
The questionnaire assessed self-reported symptoms in-
cluding fatigue, pain, gastrointestinal, cognitive, neuro-
logical and infection related symptoms. Participants were
asked to indicate how much they had been affected by
each of the symptoms over the last seven days. The ques-
tionnaire was Likert scored with responses ranging from 0
“not at all” to 4 “extremely”. Indices were then generated
from the individual questions. The urinary amino acid
analyses were performed using the commercial EZ:Faast™
derivatisation method (esterification of amino acids) fol-
lowed by gas chromatography/flame ionisation detection
(GC/FID) [6].
The sample size was based upon the research team’s
experience of amino acid profiling and the effects of
supplementation in humans and was projected to pro-
vide sufficient power to determine whether the supple-
ment had the potential to alter amino acid homeostasis.
Comparisons were made between the pre- and post-
supplement symptom and amino acid profiles of the
cohort. The preliminary nature of the study meant that a
placebo group was not included at this stage of product
assessment. Statistical analyses were performed using
Statistica™ release 7.0 (Statsoft Inc., Tulsa, USA). NVivo
9 (QSR International Pty Ltd.) for qualitative data wasused to assess open-ended questions regarding supple-
ment experience. Mann–Whitney U test was used to
analyse the Chalder fatigue scale scores. Amino acid data
were assessed using forward stepwise discriminant func-
tion analysis and Mann–Whitney U test performed on
arcsine transformed data. Levels of statistical significance
were set at P<0.05.
The study was approved by the University of Newcastle
Human Research Ethics Committee (H-2010-1313) and
was registered with the Australian New Zealand Clinical
Trials Registry (ACTRN12611000403932). All participants
provided informed written consent before taking part in
the trial.
Results and discussion
Seventeen men reporting symptoms of sub-health were
enrolled in the current study. Potential participants were
included in the study if they were reportedly free of a
diagnosis of any significant medical condition. Amongst
the men included in the study, one participant reported
controlled hypertension and another reported having
previously suffered with sleep apnoea/narcolepsy but in-
dicated that they were currently free from any significant
medical condition. The mean age of the subjects was
37.6 ± 11.7 years (mean ± SD, range 19–65 years) and
the mean body mass index was 27.7 ± 4.2 kg/m2.
Following 30 days of amino acid supplementation, a
significant reduction was seen in the evaluations of total
fatigue and physical fatigue scores compared with the
initial evaluations prior to supplementation (Table 1).
These reductions in scores from the Chalder fatigue
questionnaire represented reduced levels of fatigue in
subjects following supplementation with Fatigue Reviva™
in this group of relatively healthy men reporting symp-
toms of sub-health.
The participants were asked to provide answers to
questions regarding their experience of using the supple-
ment in an endeavour to determine whether the product
required further development. When asked “If given the
opportunity would you continue to use the supplement?”
12 of 16 men (75%) indicated that they would continue.
In addition, when asked “Do you think that the dietary
Table 3 Types and number of comments regarding
experience of supplement use provided by participants
after 30 days of dietary supplementation



















Note: Fifteen participants provided a comment/s. *“GIT symptoms” was further
broken down into the types of symptoms reported.
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(65%) responded “Yes” whilst six indicated “No”. Partici-
pants were also invited to provide comments regarding
the ability of the Fatigue Reviva™ supplement to improve
their health (Table 2). Five of the participants provided
comments indicating that the supplement had increased
their levels of energy or reduced tiredness (Table 2).
When participants were asked to “Please describe your
experience of using the supplement” 5 of the subjects
provided positive comments indicating that they felt the
supplement had improved their levels of energy (Table 3)
whilst one of the men specifically reported an improve-
ment in gastrointestinal tract (GIT) symptoms. Amongst
the negative responses provided, 4 participants indicated
that they had experienced GIT symptoms when using
the supplement. These four individuals attributed an
increase in abdominal pain/discomfort, flatulence and in
one instance diarrhoea to supplement use (Table 3).
Changes in GIT symptoms, both negative and positive,
may be attributed to the composition of the supplement.
In addition to amino acids, the nutritional supplement
contained the prebiotic fructooligosaccharide (FOS) [23].
The ingestion of FOS has been shown to promote the
growth of gastrointestinal bifidobacteria which are
thought to have a number of health benefits including
lowering blood levels of neurotoxic ammonia [24]. The
FOS was considered an important component as it is
fermented by the gut bacteria in the large intestine
resulting in the formation of short-chain fatty acids,
which can also have beneficial effects. These short chain
fatty acids can potentially stimulate the growth of bac-
teria, including lactobacilli and bifidobacteria [25]. The
FOS also played an important role in maintaining the
palatability of the supplement without direct uptake byTable 2 Types and number of comments regarding
perceived improvement in health provided by
participants after 30 days of dietary supplementation





Aided recovery from mild illness 1/17





GIT symptoms (flatulence) 1/17
Fatigue not improved 1/17
Note: Thirteen participants provided a comment/s.the human body and thus provided vital functions of
sweetener and GIT bacterial enhancement, without
significant impact on sugar loading and avoiding the use
of artificial sweeteners.
Five (5) out of 17 subjects reported some adverse
symptoms including flatulence and discomfort, which
has been previously reported with FOS use at much
higher doses [26]. In contrast, other subjects in this
study reported benefits including reduced bowel irrita-
tion and GIT improvement which may be associated
with the potential enhancement of bifidobacteria which
have been reported to be mediated by FOS [23]. The
symptom questionnaires and urine excretion data for
these five subjects were further evaluated in comparison
to the remaining 12 subjects to see whether any issues
of sub-health might be identified as markers of individ-
uals likely to experience GIT discomfort on supplemen-
tation. The 86-item symptom questionnaire enabled the
evaluation of symptom groups or indices including a
broadly based “neurological” index. This index included
assessments of the following symptoms reported in the
prior 7 days: faintness or dizziness; crying easily; tinnitus;
photophobia; mind going blank; trouble concentrating;
hypersensitivity; mental fatigue; and panic attacks. The
mean neurological index score for the 5 subjects reporting
the adverse GIT symptoms, was significantly higher prior
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subjects as shown in Table 4 (P<0.004). It should be
noted that the maximum score possible for the index
was 10 which shows that the mean scores <3 by these
subjects were consistent with the classification of ex-
periencing only sub-health issues. Both GIT symptom
subgroups recorded lower mean total fatigue scores fol-
lowing supplementation although only the GIT symptom
free group recorded a statistically significant improvement
in fatigue (Mann–Whitney U test, P < 0.04). Both pre-
and post-supplementation, the sub-group reporting GIT
symptoms recorded higher mean total fatigue scores than
the GIT symptom free group. Although these findings did
not reach levels of statistical significance, it is possible that
with a larger cohort it may be shown that those individuals
suffering from GIT symptoms also experience higher
levels of fatigue. The group of 5 subjects with GIT
symptoms was also characterised by increases in the
relative abundances of asparagine, hydroxylysine and
hydroxyproline in the urine excretion profile. Following
supplementation these changes in amino acids, along
with the neurological difficulties indicated by the in-
creased neurological index score, were consistent with a
process of normalisation for the 5 subjects reporting the
GIT symptoms (Table 4).
Future investigations should continue to determine
whether these symptom profiles or urine excretion anom-
alies of GIT-sensitive subjects could be used as predictors
for those people more likely to experience GIT issues with
taking the Fatigue Reviva™ supplement. These predictors,
if validated, may have future use to identify people with aTable 4 Differences between subjects reporting GIT problems
supplementation
Pre-supplementation























Statistical test: Mann–Whitney U. n = 5 and 12 for the participants reporting GIT sym
ns = statistically non-significant.lower tolerance for FOS and the development of a product
with reduced FOS content may be warranted.
The analyses of the urine excretion profiles of amino
acids pre- and post-supplementation for the entire co-
hort revealed significant increases in the relative abun-
dances of isoleucine, valine, glutamic acid and proline
following supplementation whilst significant reductions
were seen in glutamine and ornithine (Table 5). Signifi-
cant increases in the percentage of total essential amino
acids and total BCAAs, which make up approximately
one third of the essential amino acids in muscle proteins
[27], were also seen after supplementation. These results
were interpreted to reflect an altered homeostasis for
amino acids in the body since the relative abundances in
composition of urine were altered. The alterations in
urinary excretion profiles did not reflect general in-
creases in urinary amino acid output following elevated
intake of the Fatigue Reviva™ supplement. This interpret-
ation was supported by the significant decrease in glu-
tamine observed after the supplementation period.
Glutamine is a major component of the amino acid sup-
plement and the diminished output relative to other
amino acids supports the hypothesis of an altered
homeostasis. Glutamine promotes the functioning of the
immune system and is the most abundant free amino
acid in plasma and muscle [28]. During stress there is an
increase in glutamine efflux from skeletal muscle and it
has been proposed that in catabolic states glutamine
may become conditionally essential [29]. Provision of
the broad-spectrum amino acid Fatigue Reviva™ supple-
ment which includes glutamine, would have a potentialand those who did not report GIT symptoms following
Post-supplementation







0.004 1.0 0.4 ns
ns 12.6 8.9 ns
< 0.03 6.11% 4.89% ns
< 0.05 1.72% 1.32% ns
< 0.04 0.65% 0.52% ns
ptoms and those who did not report GIT symptoms respectively.
Table 5 Univariate analysis of the relative abundance of urinary amino acids and derivatives: comparison between
participants pre- and post-supplementation
Amino acid Pre-supplement relative
abundance % mean (SEM)
Post-supplement relative
abundance % mean (SEM)
P value
Alanine 5.80 (0.34) 5.09 (0.32) ns
Glycine 20.82 (1.08) 18.08 (1.58) ns
α-aminobutyric acid 0.20 (0.05) 0.21 (0.04) ns
Valine 1.00 (0.06) 1.24 (0.08) < 0.04
β-aminoisobutyric acid 3.11 (0.49) 4.48 (1.14) ns
Leucine 0.70 (0.04) 0.70 (0.04) ns
Isoleucine 0.17 (0.04) 0.35 (0.03) < 0.02
Threonine 2.45 (0.14) 2.35 (0.16) ns
Serine 5.94 (0.39) 5.42 (0.37) ns
Proline 0.31 (0.07) 0.51 (0.08) < 0.04
Asparagine 5.32 (0.35) 5.25 (0.52) ns
Aspartic acid 0.34 (0.08) 0.48 (0.06) ns
Methionine 0.29 (0.04) 0.35 (0.04) ns
Hydroxyproline 0.41 (0.07) 0.56 (0.08) ns
Glutamic acid 0.33 (0.07) 0.70 (0.09) < 0.008
Phenylalanine 1.07 (0.07) 1.20 (0.10) ns
α-aminoadipic acid 1.86 (0.33) 1.65 (0.29) ns
α-aminopimelic acid 0.15 (0.05) 0.10 (0.03) ns
Glutamine 12.61 (0.85) 8.75 (0.62) < 0.003
Ornithine 1.22 (0.11) 0.99 (0.10) < 0.04
Glycine-proline dipeptide 2.06 (0.22) 1.99 (0.22) ns
Lysine 6.53 (1.54) 6.36 (1.88) ns
Histidine 17.70 (1.12) 22.59 (2.71) ns
Hydroxylysine 1.29 (0.12) 1.44 (0.16) ns
Tyrosine 1.92 (0.13) 2.07 (0.16) ns
Proline-hydroxyproline dipeptide 3.04 (0.38) 2.84 (0.31) ns
Tryptophan 1.31 (0.10) 1.40 (0.11) ns
Cystathionine 0.86 (0.18) 1.37 (0.33) ns
Cystine 1.21 (0.12) 1.47 (0.20) ns
Total EAA 31.22 (1.38) 36.55 (2.79) < 0.05
Total BCAA 1.87 (0.13) 2.29 (0.11) < 0.02
Statistical test: Mann–Whitney U test, P < 0.05. Values are the mean (SEM) and are expressed as amino acid relative abundance (percentage). Analysis performed
on arcsine transformed data. ns = statistically non-significant.
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mote function and growth of immune cells and alter the
metabolic equilibrium in the body.
The alterations in the relative abundance composition of
key amino acids supported a re-adjustment of amino acid
homeostasis as opposed to a general increased throughput
of ingested amino acids. The results of univariate analyses
were supported by multivariate analysis of the urinary
amino acid data. Discriminant function analysis of the
urine excretion data revealed that it was possible to differ-
entiate between the group’s pre- and post-supplementurine excretion profiles (Wilks’ Lambda = 0.07, P<0.0001).
An ability to discriminate between groups based upon
their pre- and post-supplement profiles may lead to a cap-
acity in the future to apply urine testing to specifically
identify those subjects who might benefit from supple-
mentation with Fatigue Reviva™.
Conclusion
The evaluation of the results for the cohort of 17 males
indicated that the use of the Fatigue Reviva™ supplement
for 30 days resulted in significantly reduced levels of
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profiles. In total, 65% of the group reported that they
perceived that the supplementation resulted in an im-
provement of their health. Only one subject reported
substantial GIT symptoms, but a further 24% of the
group reported some mild GIT symptoms of discomfort
or bloating which was thought to be associated with the
inclusion of the FOS. This group was also characterised
prior to supplementation by significant elevations of
symptoms such as “mind going blank”, and had elevated
relative excretions of asparagine, hydroxylysine and hy-
droxyproline compared to the rest of the group. Con-
versely, other participants reported improvements in
bowel irritation and GIT performance. An alternative sup-
plement formulation with reduced FOS content was pro-
posed, and the associated symptoms and urine excretion
anomalies represent potential predictors for those likely to
be GIT-sensitive to the supplement. The results of this
pilot study indicated that the Fatigue Reviva™ has the
potential to provide an effective tool for the management
of unexplained fatigue and symptoms of sub-health.
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